Sci­en­tists and star­tups re­veal new gene in­ser­tion tech­niques, though much re­mains be­hind closed doors: #AS­GCT24

Last year
Startups
R&D

iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar

Last year
R&D
News Briefing

Gink­go to cut spend­ing, lay off staff af­ter earn­ings dis­ap­point­ment

Last year
People

Tessera un­veils promis­ing in vi­vo gene edit­ing treat­ment for sick­le cell in an in­creas­ing­ly com­pet­i­tive field: ...

Last year
R&D
Cell/Gene Tx

Macro­Gen­ics in­ves­ti­gates three pa­tient deaths in Phase 2 prostate can­cer drug tri­al

Last year
R&D

Lykos shores up com­mer­cial team for MD­MA drug; For­mer J&J CEO Alex Gorsky finds his next gig

Last year
People
Peer Review

FDA de­lays Mod­er­na RSV vac­cine de­ci­sion, but what's next is like­ly to be a tougher, longer climb

Last year
Pharma

Sanofi grabs a share of No­vavax's Covid vac­cine for $500M, eye­ing com­mer­cial­iza­tion, flu com­bi­na­tion

Last year
Deals
Pharma

AGC Bi­o­log­ics to cut close to 4% of staffers 'to ad­just busi­ness pri­or­i­ties'

Last year
People
Manufacturing

Af­ter FTC scruti­ny of Sanofi deal, Maze finds a new Pompe part­ner in Sh­iono­gi

Last year
Deals
R&D

BIO CEO de­fends the or­ga­ni­za­tion's about-face on the Biose­cure Act

Last year
Deals
China

Cor­rect­ed: Ex­perts to de­cide with­in a year whether to rec­om­mend Duchenne mus­cu­lar dy­s­tro­phy for new­born screen­ing

Last year
FDA+

Take­da to shut down San Diego re­search cen­ter 

Last year
People
Pharma

Ahead of like­ly ap­proval, ICER finds Geron’s ime­tel­stat is not cost-ef­fec­tive at $250,000 an­nu­al­ly

Last year
Pharma
FDA+

Across two clin­i­cal tri­als, gene ther­a­py re­stores hear­ing in chil­dren deaf since birth: #AS­GCT24

Last year
R&D
Cell/Gene Tx

Blue­bird bio starts 15 pa­tients on its three mul­ti­mil­lion-dol­lar gene ther­a­pies

Last year
Pharma
Cell/Gene Tx

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Last year
Financing
Marketing

Charles Riv­er touts first-quar­ter man­u­fac­tur­ing rev­enue, says Chi­na bill is ‘net pos­i­tive’

Last year
China
Manufacturing

Nu­cle­us Ra­dio­Phar­ma makes Art­bio’s ra­dio­phar­ma as­sets; Mi­naris man­u­fac­tures blue­bird’s Lyf­ge­nia 

Last year
Manufacturing

Rapt Ther­a­peu­tics winds down Phase 2 stud­ies of lead can­di­date in wake of clin­i­cal holds

Last year
R&D

In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

Last year
R&D
China

Roy­al­ty Phar­ma inks MS deal with Im­muNext; X4 sells its pri­or­i­ty re­view vouch­er

Last year
News Briefing

Ace­lyrin's found­ing CEO steps down, com­pa­ny scraps earn­ings call

Last year
People
Startups

Free­line un­veils ear­ly ef­fi­ca­cy sig­nal for Gauch­er gene ther­a­py: #AS­GCT24

Last year
R&D
Cell/Gene Tx
First page Previous page 159160161162163164165 Next page Last page
A service from the Financial Times